Abiraterone acetate.
Författaruppgift saknas
Drugs R D · research-article; review; journal article · DOI 10.2165/11587960-000000000-00000 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för abiraterone acetate. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
40 träffarWords of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Schmid HP, Engeler DS.
Eur Urol · comment; journal article · DOI 10.1016/j.eururo.2009.07.012Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, et al. J Clin Oncol 2008;26:4563-71.
Vogelzang NJ.
Eur Urol · comment; journal article · DOI 10.1016/j.eururo.2009.04.017Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.
J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1200/jco.2008.20.0642Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71.
Eisenberger MA.
Eur Urol · comment; journal article · DOI 10.1016/j.eururo.2008.09.035Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone driven.
Schalken JA.
Eur Urol · comment; journal article · DOI 10.1016/j.eururo.2008.08.043Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
Antonarakis ES, Eisenberger MA.
Nat Clin Pract Oncol · article-commentary; comment; journal article · DOI 10.1038/ncponc1262Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS.
J Clin Oncol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1200/jco.2007.15.9749A validated liquid chromatographic-tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma.
Martins V, Asad Y, Wilsher N, Raynaud F.
J Chromatogr B Analyt Technol Biomed Life Sci · research support, non-u.s. gov't; validation study; journal article · DOI 10.1016/j.jchromb.2006.06.010Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.
O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M.
Br J Cancer · other; clinical trial; multicenter study; journal article · DOI 10.1038/sj.bjc.6601879